Market Overview

UPDATE: Aegis Capital Raises PT on Amarin to $35

Related AMRN
UPDATE: What Amarin Would Need To Disclose To Ensure Non-Misleading Speech
First Amendment Decision a Win for Amarin and Physician Plaintiffs

Aegis Capital published a report on Amarin Corporation (NASDAQ: AMRN) that maintained its Buy rating and raised its price target from $25 to $35.

In the report, Aegis Capital wrote, "Yesterday, Amarin announced that it had secured committed non-equity financing of $100mm to fund the launch of its lead drug Vascepa (icosapent ethyl) for treatment of hypertriglyceridemia. The firm indicated that it plans to launch the drug in 1Q 2013 and will hire 250-300 sales representatives (each with 3 - 5 years of experience) to commercialize the product. Furthermore, Amarin announced yesterday that it received a positive update on an important patent that would protect Vascepa in the mixed dyslipidemia indication. We are reiterating our Buy rating and raising our price target from $25.00 to $35.00 on Amarin shares."

Aegis Capital closed Thursday at $11.95.

Latest Ratings for AMRN

Mar 2015HC WainwrightUpgradesBuy
Feb 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
Nov 2014CitigroupMaintainsNeutral

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Aegis CapitalAnalyst Color Price Target Analyst Ratings


Related Articles (AMRN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters